Evidence map›Paper›PMID 36123694›Full record

ArticleMicrobial cell factories2022

Exploring optimal Taxol® CYP725A4 activity in Saccharomyces cerevisiae.

Behnaz Nowrouzi, Liang Lungang, Leonardo Rios-Solis

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Biochemical synthesis of taxanes from mevalonate.Synthetic and systems biotechnology · 2024
    Article
  5. RewiringMetabolic engineering communications · 2024
    Article
  6. Article
  7. Way to efficient microbial paclitaxel mass production.Synthetic and systems biotechnology · 2023
    Review
  8. Article
  9. Improved production of TaxolMicrobial cell factories · 2023
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Behnaz NowrouziInstitute for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh, EH9 3BF, UK.
Liang LungangInstitute for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh, EH9 3BF, UK.
Leonardo Rios-SolisInstitute for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh, EH9 3BF, UK. Leo.rios@ncl.ac.uk.
University of Edinburgh · GB

Funding

British Council - Metabolic Engineering grant R46889Engineering and Physical Sciences Research Council EP/R513209/1
6 · The paper itself

Abstract

backgroundCYP725A4 catalyses the conversion of the first Taxol® precursor, taxadiene, to taxadiene-5α-ol (T5α-ol) and a range of other mono- and di-hydroxylated side products (oxygenated taxanes). Initially known to undergo a radical rebound mechanism, the recent studies have revealed that an intermediate epoxide mediates the formation of the main characterised products of the enzyme, being T5α-ol, 5(12)-oxa-3(11)-cyclotaxane (OCT) and its isomer, 5(11)-oxa-3(11)-cyclotaxane (iso-OCT) as well as taxadienediols. Besides the high side product: main product ratio and the low main product titre, CYP725A4 is also known for its slow enzymatic activity, massively hindering further progress in heterologous production of Taxol® precursors. Therefore, this study aimed to systematically explore the key parameters for improving the regioselectivity and activity of eukaryotic CYP725A4 enzyme in a whole-cell eukaryotic biocatalyst, Saccharomyces cerevisiae.

resultsInvestigating the impact of CYP725A4 and reductase gene dosages along with construction of self-sufficient proteins with strong prokaryotic reductases showed that a potential uncoupling event accelerates the formation of oxygenated taxane products of this enzyme, particularly the side products OCT and iso-OCT. Due to the harmful effect of uncoupling products and the reactive metabolites on the enzyme, the impact of flavins and irons, existing as prosthetic groups in CYP725A4 and reductase, were examined in both their precursor and ready forms, and to investigate the changes in product distribution. We observed that the flavin adenine dinucleotide improved the diterpenoids titres and biomass accumulation. Hemin was found to decrease the titre of iso-OCT and T5α-ol, without impacting the side product OCT, suggesting the latter being the major product of CYP725A4. The interaction between this iron and the iron precursor, δ-Aminolevulinic acid, seemed to improve the production of these diterpenoids, further denoting that iso-OCT and T5α-ol were the later products. While no direct correlation between cellular-level oxidative stress and oxygenated taxanes was observed, investigating the impact of salt and antioxidant on CYP725A4 further showed the significant drop in OCT titre, highlighting the possibility of enzymatic-level uncoupling event and reactivity as the major mechanism behind the enzyme activity. To characterise the product spectrum and production capacity of CYP725A4 in the absence of cell growth, resting cell assays with optimal neutral pH revealed an array of novel diterpenoids along with higher quantities of characterised diterpenoids and independence of the oxygenated product spectra from the acidity effect. Besides reporting on the full product ranges of CYP725A4 in yeast for the first time, the highest total taxanes of around 361.4 ± 52.4 mg/L including 38.1 ± 8.4 mg/L of T5α-ol was produced herein at a small, 10-mL scale by resting cell assay, where the formation of some novel diterpenoids relied on the prior existence of other diterpenes/diterpenoids as shown by statistical analyses.

conclusionsThis study shows how rational strain engineering combined with an efficient design of experiment approach systematically uncovered the promoting effect of uncoupling for optimising the formation of the early oxygenated taxane precursors of Taxol®. The provided strategies can effectively accelerate the design of more efficient Taxol®-producing yeast strains.

Indexed as

DiterpenesPaclitaxelAlkenesAminolevulinic AcidAntioxidantsBridged-Ring CompoundsCytochrome P-450 Enzyme SystemEpoxy CompoundsFlavin-Adenine DinucleotideHeminIronSaccharomyces cerevisiaeTaxoidsAlkenesAminolevulinic AcidAntioxidantsBridged-Ring CompoundsCytochrome P-450 Enzyme SystemDiterpenesEpoxy CompoundsFlavin-Adenine DinucleotideHeminIronPaclitaxeltaxa-4(5),11(12)dienetaxaneTaxoidsCYP725A4Cytochrome P450 monooxygenaseDiterpenoidsSaccharomyces cerevisiaeTaxadiene-5α-olTaxol®Whole-cell biocatalysis

Identifiers

PMID36123694
PMCPMC9484169
OpenAlexW4296368399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.